





























2006 Antiretrovirals in Development Pipeline

Prepared for
 Treatment Action Group
 By **Rob Camp** • updated 12/21/2006

Phase of Development	NRTI	NNRTI	PI	EI*	Integrase Inhibitors	Other
Phase I	KP-1461, mutagenic deoxyribo-nucleoside, <i>Koronis</i> 		PPL-100, <i>Merck</i>  	BMS-378806, gp120 blocker, <i>BMS</i> 	GSK364735, <i>GSK/Shionogi</i>	BI-201, Tat inhibiting mAb, <i>BioInvent</i>
	Alovudine (fosalvudine tidoxil, FLT), <i>Heidelberg Pharma</i>			TAK-652, <i>Takeda</i>		
				004, mAb, <i>Human Genome Sciences</i>  		
				Suc-HSA, fusion inhibitor, <i>Sanquin</i>		
Phase Ib/II	Racivir (PSI 5004), <i>Pharmasset</i> 	BILR 355/r BS, <i>Boehringer Ingelheim</i>  		AMD-070, CXCR4 antagonist, <i>Anormed</i>		Valproic acid, [<i>Depakote™</i> , <i>Abbott</i>], ACTG
	Apricitabine (AVX 754), <i>Avexa</i> 			PRO-140, MAb, <i>Progenics</i>  		Bevirimat (PA-457), Budding inhibitor, <i>Panacos</i>

	Elvucitabine (ACH-126), <i>Achillion</i>   			INCB9471, CCR5 inhibitor, <i>Incyte</i>		
				HGS004, CCR5 mAb, <i>Human Genome Sciences</i>		
Phase II		Rilpivirine, TMC-278, <i>Tibotec/J&J</i>	Brecanavir/r (640385) , <i>GSK</i>	Vicriviroc , CCR5 antagonist, <i>Schering Plough</i>    	GS-9137, <i>Gilead</i>	
				TNX-355, Anti-CD4 MAb, <i>Tanox/Biogen</i>		
Phase III		Etravirine (TMC125), <i>Tibotec/J&J</i>		Maraviroc , CCR5 antagonist, <i>Pfizer</i>      	MK-0518, <i>Merck</i>	
 Notes: * entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry.  link to abstract/background material from CROI 2005. <i>On hold or stopped.</i>  link to abstract/background material from XIIIth Conference on Retroviruses and Opportunistic Infections, Denver, US, 5-8 February, 2006.						